Harrow Needs A Big Third-Quarter Jump To Keep Its Back-Half Revenue Promise Credible

Harrow has spent most of 2026 asking investors to trust a calendar. The eyecare drugmaker's product demand has been climbing quarter after quarter, yet reported revenue and margins keep lagging, and management's reaffirmed full-year outlook now depends on a second half roughly twice the size of the first. The third-quarter report, due after the close on November 9, is the first real installment on that promise, and the stock's slide suggests the market wants proof rather than another pledge.

Wall Street expects revenue of about $99.9 million, up 39.4% from $71.6 million a year earlier and a jump of roughly 41% from the $70.7 million booked in the second quarter. Consensus earnings of $0.17 a share would mark a return to profit after a loss of $0.34 last quarter, though they would still sit about 48.5% below the year-ago $0.33. That contrast matters: revenue is expected to grow sharply while profit shrinks, a sign that the costs of new launches and the pending Tervaya acquisition, which management said would add about $20 million in annual selling expenses, are absorbing much of the top-line gain.

The guidance math is where the tension sits. Harrow reaffirmed 2026 revenue of $350 million to $365 million, and the full-year consensus of $350.05 million is pinned to the very bottom of that range. With first-half revenue of only about $115 million, hitting even the low end requires around $235 million in the back half. If the third quarter lands near $100 million, the fourth quarter would still need roughly $135 million. Analysts, in other words, are already discounting the top of the range, and a third-quarter shortfall would leave little room to defend the floor. The same steep curve applies to the $80 million to $100 million adjusted EBITDA target, which looks ambitious after a combined first-half loss of about $14 million.

The ingredients for a big quarter were laid out last time. Vevye posted record revenue of $29.4 million, prescriptions outgrew its branded market, and share reached 14.6% in June. A coverage win at a top-three pharmacy benefit manager took effect August 1, so the third quarter should show whether newly unblocked lives translate into paid scripts at healthy net prices. That last point is critical, since an estimated $8 million gross-to-net miss sank the first quarter, and management acknowledged a widening gap between its internal prescription data and third-party figures. For Iheezo, record unit demand and a roughly 25% net price increase effective July 1 should finally show up in dollars, provided in-office conversion is offsetting the lost surgery-center reimbursement and channel inventory has stopped normalizing. Gross margin climbing back from 71% toward the high-70s target would be the clearest sign that the mix and pricing story is working. Pipeline updates on the GMELT pre-NDA meeting and Iheezo retina data are useful extras but unlikely to rescue a soft revenue print.

The market has already rendered a skeptical verdict. Shares have fallen 27.6% since the last report, trailing the S&P 500 by about 25 percentage points, and at $28.24 they trade well below the 200-day moving average of $38.40, near the post-earnings low of $26.96 and beneath last quarter's low. Sentiment is bearish and slightly more so than heading into the prior report. That lowered bar cuts both ways: a clean quarter could spark relief, while another miss would reinforce a pattern of soft results paired with big promises.

The central question is simple. Harrow must show that record demand is finally converting into recognized revenue and margin at the pace its guidance requires. A print near $100 million with improving gross-to-net and margins keeps the full-year story alive; anything short of that likely forces a guidance reset.

This earnings preview was originally published on Earnings Whispers.

This article is for informational purposes only and is not investment advice. Earnings Whispers and its staff may hold positions in the securities mentioned. It is AI-assisted, based on proprietary Earnings Whispers data and company reports, and edited by Earnings Whispers staff.